Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 10, 2016, Pages 2616-2627

  Bragazzi, Nicola Luigi ^a   Orsi, Andrea ^a,b   Ansaldi, Filippo ^a,b   Gasparini, Roberto ^a   Icardi, Giancarlo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

cutaneous vaccination; Fluzone ; influenza; Intanza ; intradermal vaccine; microneedle device; skin immunization

Indexed keywords

IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; SUBUNIT VACCINE;

CROSS PROTECTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; JET INJECTOR; MECHANICAL STRESS; META ANALYSIS (TOPIC); MICRONEEDLE; MULTICENTER STUDY (TOPIC); PATIENT ATTITUDE; PATIENT PREFERENCE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; IMMUNOLOGY; INFLUENZA, HUMAN; INTRADERMAL DRUG ADMINISTRATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL;

EID: 84992036463     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1187343     Document Type: Review

References (108)

1. R.Gasparini, D.Amicizia, P.L.Lai, N.L.Bragazzi, D.Panatto. Compounds with anti-influenza activity:present and future of strategies for the optimal treatment and management of influenza. Part I:Influenza life-cycle and currently available drugs. J Prev Med Hyg 2014 Sep; 55(3):69-85.
2. A.E.Fiore, C.B.Bridges, J.M.Katz, N.J.Cox. Inactivated influenza vaccines. In (Eds. S.A.Plotkin, W.A.Orenstein, P.A.Offit):Vaccines. Sixth edition. Section 2:Licensed vaccines. 2013; 257-93. Elsevier, ISBN:978-1-4557-0090-5
3. F.Carrat, E.Vergu, N.M.Ferguson, M.Lemaitre, S.Cauchemez, S.Leach, A.J.Valleron. Time lines of infection and disease in human influenza:a review of volunteer challenge studies. Am J Epidemiol 2008Apr1; 167(7):775-85; http://dx.doi.org/10.1093/aje/kwm375
4. R.Gasparini, D.Amicizia, P.L.Lai, D.Panatto. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum Vaccin Immunother 2012 Jan; 8(1):21-8; http://dx.doi.org/10.4161/hv.8.1.17622
5. N.de Francisco Shapovalova, M.Donadel, M.Jit, R.Hutubessy. A systematic review of the social and economic burden of influenza in low- and middle-income countries. Vaccine 2015Nov27; 33(48):6537-44; http://dx.doi.org/10.1016/j.vaccine.2015.10.066
6. World Health Organization (WHO). Influenza (Seasonal), factsheet n° 211. Available at http://​www.​who.​int/​mediacentre/​factsheets/​fs211/​en/​
7. W.Smith, C.H.Andrewes, P.P.Laidlaw. A virus obtained from influenza patients. Lancet 1933; ii:66-88; http://dx.doi.org/10.1016/S0140-6736(00)78541-2
8. R.Gasparini, D.Amicizia, P.L.Lai, N.L.Bragazzi, D.Panatto. Compounds with anti-influenza activity:present and future of strategies for the optimal treatment and management of influenza. Part II:Future compounds against influenza virus. J Prev Med Hyg 2014 Dec; 55(4):109-29
9. Z.Shen, K.Lou, W.Wang. New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharm Sin B 2015 Sep; 5(5):419-30; http://dx.doi.org/10.1016/j.apsb.2015.07.006
10. J.J.Treanor. Prospects for Broadly Protective Influenza Vaccines. Am J Prev Med 2015 Dec; 49(6 Suppl 4):S355-63; http://dx.doi.org/10.1016/j.amepre.2015.09.012
11. K.Stöhr, M.P.Kieny, D.Wood. Influenza pandemic vaccines:how to ensure a low-cost, low-dose option. Nat Rev Microbiol 2006 Aug; 4(8):565-6; http://dx.doi.org/10.1038/nrmicro1482
12. R.Gasparini, D.Amicizia, P.L.Lai, D.Panatto. Aflunov(®):a prepandemic influenza vaccine. Expert Rev Vaccines 2012 Feb; 11(2):145-57; http://dx.doi.org/10.1586/erv.11.170
13. F.He, S.Leyrer, J.Kwang. Strategies towards universal pandemic influenza vaccines. Expert Rev Vaccines 2015Dec5:1-11. [Epub ahead of print]
14. M.M.Cox, J.R.Hollister. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009 Jun; 37(3):182-9; http://dx.doi.org/10.1016/j.biologicals.2009.02.014
15. M.M.Cox, R.Izikson, P.Post, L.Dunkle. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines 2015 Jul; 3(4):97-108; http://dx.doi.org/10.1177/2051013615595595
16. M.M.Cox, P.A.Patriarca, J.Treanor. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses 2008 Nov; 2(6):211-9; http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x
17. L.P.Yang. Recombinant trivalent influenza vaccine (flublok(®)):a review of its use in the prevention of seasonal influenza in adults. Drugs 2013 Aug; 73(12):1357-66; http://dx.doi.org/10.1007/s40265-013-0103-6
18. I.Manini, A.Domnich, D.Amicizia, S.Rossi, T.Pozzi, R.Gasparini, D.Panatto, E.Montomoli. Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines 2015 Jun; 14(6):789-804; http://dx.doi.org/10.1586/14760584.2015.1039520
19. K.McKeage. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent):a review of its use in the prevention of disease caused by influenza A and B. Drugs 2013 Sep; 73(14):1587-94; http://dx.doi.org/10.1007/s40265-013-0114-3
20. K.McKeage. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent):a review of its use in the prevention of disease caused by influenza A and B. Drugs 2013 Sep; 73(14):1587-94; http://dx.doi.org/10.1007/s40265-013-0114-3
21. M.P.Curran, I.Leroux-Roels. Inactivated split-virion seasonal influenza vaccine (Fluarix):a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs 2010Aug20; 70(12):1519-43; http://dx.doi.org/10.2165/11205020-000000000-00000
22. H.M.El Sahly, W.A.Keitel. Clinical data on Fluarix:an inactivated split seasonal influenza vaccine. Expert Rev Vaccines 2008 Aug; 7(6):713-9; http://dx.doi.org/10.1586/14760584.7.6.713
23. G.W.Rose, C.L.Cooper. Fluarix, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 2006 Mar; 6(3):301-10; http://dx.doi.org/10.1517/14712598.6.3.301
24. R.Gasparini, P.Lai. Utility of virosomal adjuvated influenza vaccines:a review of the literature. J Prev Med Hyg 2010 Mar; 51(1):1-6
25. B.C.Childress, J.D.Montney, E.A.Albro. Making evidence-based selections of influenza vaccines. Hum Vaccin Immunother 2014; 10(9):2729-32; PMID:25483499; http://dx.doi.org/10.4161/hv.29340
26. R.Gasparini, D.Amicizia, P.L.Lai, D.Panatto. Live attenuated influenza vaccine–a review. J Prev Med Hyg 2011 Sep; 52(3):95-101
27. M.T.Osterholm, N.S.Kelley, A.Sommer, E.A.Belongia. Efficacy and effectiveness of influenza vaccines:a systematic review and meta-analysis. Lancet Infect Dis 2012 Jan; 12(1):36-44; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
28. T.Jefferson, C.Di Pietrantonj, L.A.Al-Ansary, E.Ferroni, S.Thorning, R.E.Thomas. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010Feb17; (2):CD004876.
29. Centers for Disease Control and Prevention (CDC). FluVaxView. Available at http://www.cdc.gov/flu/fluvaxview/
30. R.L.Atmar, S.M.Patel, W.A.Keitel. Intanza(®):a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 2010; 9:1399-409; PMID:21105776; http://dx.doi.org/10.1586/erv.10.134
31. L.R.Clayville. Influenza update:a review of currently available vaccines. P T 2011 Oct; 36(10):659-84
32. J.E.Foy, T.Hendriksz, P.Malouf, A.Tobin. Acceptability of fluzone intradermal vaccine to patients and vaccine administrators. J Am Osteopath Assoc 2013 Feb; 113(2):134-43.
33. G.Icardi, A.Orsi, A.Ceravolo, F.Ansaldi. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system. Hum Vaccin Immunother 2012 Jan; 8(1):67-75; http://dx.doi.org/10.4161/hv.8.1.18419
34. F.Ansaldi, P.Durando, G.Icardi. Intradermal influenza vaccine and new devices:a promising chance for vaccine improvement. Expert Opin Biol Ther 2011 Mar; 11(3):415-27; http://dx.doi.org/10.1517/14712598.2011.557658
35. S.J.Sullivan, R.Jacobson, G.A.Poland. Advances in the vaccination of the elderly against influenza:role of a high-dose vaccine. Expert Rev Vaccines 2010 Oct; 9(10):1127-33; http://dx.doi.org/10.1586/erv.10.117
36. L.Sticchi, M.Alberti, C.Alicino, P.Crovari. The intradermal vaccination:past experiences and current perspectives. J Prev Med Hyg 2010 Mar; 51(1):7-14
37. J.K.Hickling, K.R.Jones, M.Friede, D.Zehrung, D.Chen, D.Kristensen. Intradermal delivery of vaccines:potential benefits and current challenges. Bull World Health Organ 2011Mar1; 89(3):221-6; http://dx.doi.org/10.2471/BLT.10.079426
38. P.Di Meglio, G.K.Perera, F.O.Nestle. The multitasking organ:recent insights into skin immune function. Immunity 2011Dec23; 35(6):857-69; http://dx.doi.org/10.1016/j.immuni.2011.12.003
39. G.K.Menon, G.W.Cleary, M.E.Lane. The structure and function of the stratum corneum. Int J Pharm 2012Oct1; 435(1):3-9; http://dx.doi.org/10.1016/j.ijpharm.2012.06.005
40. J.A.Bouwstra, M.Ponec. The skin barrier in healthy and diseased state. Biochim Biophys Acta 2006 Dec; 1758(12):2080-95; http://dx.doi.org/10.1016/j.bbamem.2006.06.021
41. H.S.Gill, S.M.Kang, F.S.Quan, R.W.Compans. Cutaneous immunization:an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv 2014 Apr; 11(4):615-27; http://dx.doi.org/10.1517/17425247.2014.885947
42. P.H.Lambert, P.E.Laurent. Intradermal vaccine delivery:will new delivery systems transform vaccine administration? Vaccine 2008Jun19; 26(26):3197-208; http://dx.doi.org/10.1016/j.vaccine.2008.03.095
43. M.Pasparakis, I.Haase, F.O.Nestle. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 2014 May; 14(5):289-301; http://dx.doi.org/10.1038/nri3646
44. J.M.Richmond, J.E.Harris. Immunology and skin in health and disease. Cold Spring Harb Perspect Med 2014Dec1; 4(12):a015339; http://dx.doi.org/10.1101/cshperspect.a015339
45. J.D.Bos, M.L.Kapsenberg. The skin immune system Its cellular constituents and their interactions. Immunol Today 1986 Jul-Aug; 7(7-8):235-40; http://dx.doi.org/10.1016/0167-5699(86)90111-8
46. J.W.Streilein. Skin-associated lymphoid tissues (SALT):origins and functions. J Invest Dermatol 1983 Jun; 80 Suppl:12s-16s
47. A.Boltjes, F.van Wijk. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol 2014Apr1; 5:131.
48. E.Klechevsky, R.Morita, M.Liu, Y.Cao, S.Coquery, L.Thompson-Snipes, F.Briere, D.Chaussabel, G.Zurawski, A.K.Palucka, Y.Reiter, J.Banchereau, H.Ueno. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008Sep19; 29(3):497-510; http://dx.doi.org/10.1016/j.immuni.2008.07.013
49. B.E.Clausen, P.Stoitzner. Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses. Front Immunol 2015Oct22; 6:534.
50. R.M.Steinman. Decisions about dendritic cells:past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/annurev-immunol-100311-102839
51. I.Leroux-Roels, F.Weber. Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Hum Vaccin Immunother 2013 Jan; 9(1):115-21; http://dx.doi.org/10.4161/hv.22342
52. S.Al-Zahrani, M.Zaric, C.McCrudden, C.Scott, A.Kissenpfennig, R.F.Donnelly. Microneedle-mediated vaccine delivery:harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv 2012 May; 9(5):541-50; http://dx.doi.org/10.1517/17425247.2012.676038
53. M.Tozuka, T.Oka, N.Jounai, G.Egawa, K.J.Ishii, K.Kabashima, F.Takeshita. Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine. J Dermatol Sci 2016 Apr; 82(1):38-45; http://dx.doi.org/10.1016/j.jdermsci.2015.11.008
54. A.C.Depelsenaire, S.C.Meliga, C.L.McNeilly, F.E.Pearson, J.W.Coffey, O.L.Haigh, C.J.Flaim, I.H.Frazer, M.A.Kendall. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. J Invest Dermatol 2014 Sep; 134(9):2361-70; http://dx.doi.org/10.1038/jid.2014.174
55. P.Matzinger. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045; PMID:8011301; http://dx.doi.org/10.1146/annurev.iy.12.040194.005015
56. P.Matzinger. The danger model:a renewed sense of self. Science 2002Apr12; 296(5566):301-5; http://dx.doi.org/10.1126/science.1071059
57. T.A.Smith-Norowitz, M.Kusonruksa, D.Wong, M.M.Norowitz, R.Joks, H.G.Durkin, M.H.Bluth. Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in serum of children and adults following influenza A vaccination with subsequent H1N1 infection:a case study. J Inflamm Res 2012; 5:111-6; PMID:23097613; http://dx.doi.org/10.2147/JIR.S34152
58. E.E.Kis, G.Winter, J.Myschik. Devices for intradermal vaccination. Vaccine 2012Jan11; 30(3):523-38; http://dx.doi.org/10.1016/j.vaccine.2011.11.020
59. D.G.Koutsonanos, R.W.Compans, I.Skountzou. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 2013; 785:121-32; PMID:23456844; http://dx.doi.org/10.1007/978-1-4614-6217-0_13
60. R.J.Pettis, A.J.Harvey. Microneedle delivery:clinical studies and emerging medical applications. Ther Deliv 2012 Mar; 3(3):357-71; http://dx.doi.org/10.4155/tde.12.13
61. M.Hultström, N.Roxhed, L.Nordquist. Intradermal insulin delivery:a promising future for diabetes management. J Diabetes Sci Technol 2014 May; 8(3):453-7; http://dx.doi.org/10.1177/1932296814530060
62. R.J.Narayan. Transdermal delivery of insulin via microneedles. J Biomed Nanotechnol 2014 Sep; 10(9):2244-60; http://dx.doi.org/10.1166/jbn.2014.1976
63. G.Senti, T.M.Kündig. Novel Delivery Routes for Allergy Immunotherapy:Intralymphatic, Epicutaneous, and Intradermal. Immunol Allergy Clin North Am 2016 Feb; 36(1):25-37; http://dx.doi.org/10.1016/j.iac.2015.08.006
64. S.Spanos, R.Booth, H.Koenig, K.Sikes, E.Gracely, I.K.Kim. Jet Injection of 1% buffered lidocaine versus topical ELA-Max for anesthesia before peripheral intravenous catheterization in children:a randomized controlled trial. Pediatr Emerg Care 2008; 24(8):511-5; PMID:18645542; http://dx.doi.org/10.1097/PEC.0b013e31816a8d5b
65. A.Ferayorni, R.Yniguez, M.Bryson, B.Bulloch. Needle-free jet injection of lidocaine for local anesthesia during lumbar puncture:a randomized controlled trial. Pediatr Emerg Care 2012; 28(7):687-90; PMID:22743744; http://dx.doi.org/10.1097/PEC.0b013e31825d210b
66. J.Cázares-Delgadillo, A.Ganem-Rondero, Y.N.Kalia. Human growth hormone:new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur J Pharm Biopharm 2011 Jun; 78(2):278-88; http://dx.doi.org/10.1016/j.ejpb.2011.01.006
67. S.Fabi, H.Sundaram. The potential of topical and injectable growth factors and cytokines for skin rejuvenation. Facial Plast Surg 2014 Apr; 30(2):157-71; http://dx.doi.org/10.1055/s-0034-1372423
68. P.E.Laurent, S.Bonnet, P.Alchas, P.Regolini, J.A.Mikszta, R.Pettis, N.G.Harvey. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007Dec17; 25(52):8833-42; http://dx.doi.org/10.1016/j.vaccine.2007.10.020
69. J.B.Alarcon, A.W.Hartley, N.G.Harvey, J.A.Mikszta. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 2007 Apr; 14(4):375-81; http://dx.doi.org/10.1128/CVI.00387-06
70. Y.-C.Kim, J.-H.Park, M.R.Prausnitz. Microneedles for drug and vaccine delivery. Adv Drug Del Rev 2012; 64:1547-68; http://dx.doi.org/10.1016/j.addr.2012.04.005
71. S.H.Bariya, M.C.Gohel, T.A.Mehta, O.P.Sharma. Microneedles:an emerging transdermal drug delivery system. J Pharm Pharmacol 2012; 64(1):11-29; PMID:22150668; http://dx.doi.org/10.1111/j.2042-7158.2011.01369.x
72. M.R.Prausnitz, J.A.Mikszta, M.Cormier, A.K.Andrianov. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009; 333:369-93; PMID:19768415
73. B.Camilloni, M.Basileo, S.Valente, E.Nunzi, A.M.Iorio. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60:A literature review. Hum Vaccin Immunother 2015; 11(3):553-63; PMID:25714138; http://dx.doi.org/10.1080/21645515.2015.1011562
74. R.Banchereau, N.Baldwin, A.M.Cepika, S.Athale, Y.Xue, C.I.Yu, P.Metang, A.Cheruku, I.Berthier, I.Gayet, et al. Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines. Nat Commun 2014Oct22; 5:5283; http://dx.doi.org/10.1038/ncomms6283
75. R.W.FrenckJr, R.Belshe, R.C.Brady, P.L.Winokur, J.D.Campbell, J.Treanor, C.M.Hay, C.L.Dekker, E.B.WalterJr, T.R.Cate, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011Aug5; 29(34):5666-74; http://dx.doi.org/10.1016/j.vaccine.2011.06.010
76. L.Coudeville, P.Andre, F.Bailleux, F.Weber, S.Plotkin. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin 2010 Oct; 6(10):841-8; http://dx.doi.org/10.4161/hv.6.10.12636
77. E.Morelon, C.Pouteil Noble, S.Daoud, R.Cahen, C.Goujon-Henry, F.Weber, P.E.Laurent, D.Kaiserlian, J.F.Nicolas. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 2010Oct4; 28(42):6885-90; http://dx.doi.org/10.1016/j.vaccine.2010.08.015
78. O.Manuel, A.Humar, C.Berutto, L.Ely, S.Giulieri, D.Lien, P.R.Meylan, J.Weinkauf, M.Pascual, R.Nador, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant 2011 Jun; 30(6):679-84; http://dx.doi.org/10.1016/j.healun.2011.01.705
79. F.Ansaldi, L.Valle, D.de Florentiis, V.Parodi, G.Murdaca, B.Bruzzone, P.Durando, M.Setti, G.Icardi. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. Hum Vaccin Immunother 2012 Aug; 8(8):1048-52; http://dx.doi.org/10.4161/hv.20347
80. Y.M.Jo, J.Y.Song, I.S.Hwang, J.Lee, S.C.Oh, J.S.Kim, S.R.Kim, W.J.Kim, H.J.Cheong. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009 Apr; 81(4):722-7; http://dx.doi.org/10.1002/jmv.21186
81. F.Marra, F.Young, K.Richardson, C.A.Marra. A meta-analysis of intradermal versus intramuscular influenza vaccines:immunogenicity and adverse events. Influenza Other Resp Viruses 2013; 7:584-603; http://dx.doi.org/10.1111/irv.12000
82. C.Pileggi, F.Lotito, A.Bianco, C.G.Nobile, M.Pavia. Immunogenicity and safety of intradermal influenza vaccine in immunocompromized patients:a meta-analysis of randomized controlled trials. BMC Infect Dis 2015Oct14; 15:427; http://dx.doi.org/10.1186/s12879-015-1161-z
83. R.Arnou, G.Icardi, M.De Decker, A.Ambrozaitis, M.P.Kazek, F.Weber, P.Van Damme. Intradermal influenza vaccine for older adults:a randomized controlled multicenter phase III study. Vaccine 2009Dec9; 27(52):7304-12; http://dx.doi.org/10.1016/j.vaccine.2009.10.033
84. D.Holland, R.Booy, F.De Looze, P.Eizenberg, J.McDonald, J.Karrasch, M.McKeirnan, H.Salem, G.Mills, J.Reid, F.Weber, M.Saville. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults:a randomized controlled trial. J Infect Dis 2008Sep1; 198(5):650-8; http://dx.doi.org/10.1086/590434
85. P.Tsang, G.J.Gorse, C.B.Strout, M.Sperling, D.P.Greenberg, A.Ozol-Godfrey, C.DiazGranados, V.Landolfi. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age:a randomized, controlled, phase II trial. Vaccine 2014May1; 32(21):2507-17; http://dx.doi.org/10.1016/j.vaccine.2013.09.074
86. S.Hoon Han, J.Hee Woo, F.Weber, W.Joo Kim, K.Ran Peck, S.Il Kim, Y.Hwa Choi, J.Myung Kim. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults:a multicenter, randomized trial. Hum Vaccin Immunother 2013 Sep; 9(9):1971-7; http://dx.doi.org/10.4161/hv.25295
87. F.Ansaldi, A.Orsi, D.de Florentiis, V.Parodi, E.Rappazzo, M.Coppelli, P.Durando, G.Icardi. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60:evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother 2013 Mar; 9(3):591-8; http://dx.doi.org/10.4161/hv.23240
88. F.Ansaldi, P.Canepa, A.Ceravolo, L.Valle, D.de Florentiis, R.Oomen, F.R.Vogel, M.Denis, S.I.Samson, G.Icardi. Intanza(®) 15 mg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012Apr16; 30(18):2908-13; http://dx.doi.org/10.1016/j.vaccine.2012.02.003
89. P.L.Moro, T.Harrington, T.Shimabukuro, M.Cano, O.I.Museru, D.Menschik, K.Broder. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013. Vaccine 2013Oct9; 31(43):4984-7; http://dx.doi.org/10.1016/j.vaccine.2013.08.001
90. G.J.Gorse, A.R.Falsey, C.M.Johnson, D.Morrison, D.L.Fried, J.E.Ervin, D.P.Greenberg, A.Ozol-Godfrey, V.Landolfi, P.H.Tsang. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Vaccine 2013Dec5; 31(50):6034-40; http://dx.doi.org/10.1016/j.vaccine.2013.09.012
91. G.J.Gorse, A.R.Falsey, J.A.Fling, T.L.Poling, C.B.Strout, P.H.Tsang. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. Vaccine 2013May1; 31(19):2358-65; http://dx.doi.org/10.1016/j.vaccine.2013.03.008
92. P.Eizenberg, R.Booy, N.Naser, G.Mason, D.Stamboulian, F.Weber. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011 Aug; 28(8):640-9; http://dx.doi.org/10.1007/s12325-011-0042-0
93. P.Durando, C.Alicino, M.Alberti, L.Sticchi, V.Turello, L.Marensi, A.L.Caiazzo, M.G.Panico, F.Giugliano, A.Parlato, F.Peluso, S.Sgricia, G.Icardi; Italian Intradermal Influenza Vaccine Working Group. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy:an on-field national study. Adv Ther 2012 Apr; 29(4):312-26; http://dx.doi.org/10.1007/s12325-012-0012-1
94. R.Arnou, M.Frank, T.Hagel, A.Prébet. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine:a survey of general practitioners and the general public in France and Germany. Adv Ther 2011 Jul; 28(7):555-65; http://dx.doi.org/10.1007/s12325-011-0035-z
95. C.S.Ambrose, X.Wu. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Vaccine 2013 Jan; 31(6):857-60; http://dx.doi.org/10.1016/j.vaccine.2012.12.028
96. M.Zahn, P.Pursiful, R.Carrico, C.Woods, A.Troutman. Self-immunization with live attenuated influenza vaccine in a mass vaccination clinic. Dis Med Public Health Preparedness 2013 Apr; 7(2):215-7; http://dx.doi.org/10.1017/dmp.2013.25
97. B.L.Coleman, A.J.McGeer, S.A.Halperin, J.M.Langley, Y.Shamout, A.Taddio, V.Shah, S.A.McNeil. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. Vaccine 2012Sep28; 30(44):6287-93; http://dx.doi.org/10.1016/j.vaccine.2012.08.006
98. P.A.Dhont, A.Albert, P.Brenders, A.Podwapinska, A.Pollet, D.Scheveneels, F.Tihon, I.Verheyden, J.Victor, S.I.Samson. Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season. Adv Ther 2012 Jun; 29(6):562-77; http://dx.doi.org/10.1007/s12325-012-0025-9
99. B.L.Coleman, S.A.McNeil, J.M.Langley, S.A.Halperin, A.J.McGeer. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine 2015Nov27; 33(48):6635-40; http://dx.doi.org/10.1016/j.vaccine.2015.10.095
100. S.A.Richard, C.Viboud, M.A.Miller. Evaluation of Southern Hemisphere influenza vaccine recommendations. Vaccine 2010; 28(15):2693-9; PMID:20153352; http://dx.doi.org/10.1016/j.vaccine.2010.01.053
101. A.Mosnier, S.Caini, I.Daviaud, E.Nauleau, T.T.Bui, E.Debost, B.Bedouret, G.Agius, S.van der Werf, B.Lina, et al. Clinical Characteristics Are Similar across Type A and B Influenza Virus Infections. PLoS One 2015Sep1; 10(9):e0136186; http://dx.doi.org/10.1371/journal.pone.0136186
102. G.J.Gorse, A.R.Falsey, A.Ozol-Godfrey, V.Landolfi, P.H.Tsang. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine 2015Feb25; 33(9):1151-9; http://dx.doi.org/10.1016/j.vaccine.2015.01.025
103. D.P.Greenberg, C.A.Robertson, M.J.Noss, M.M.Blatter, R.Biedenbender, M.D.Decker. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013Jan21; 31(5):770-6; http://dx.doi.org/10.1016/j.vaccine.2012.11.074
104. D.Chen, T.Bowersock, R.Weeratna, T.Yeoh. Current opportunities and challenges in intradermal vaccination. Ther Deliv 2015 Sep; 6(9):1101-8; http://dx.doi.org/10.4155/tde.15.65
105. F.Young, F.Marra. A systematic review of intradermal influenza vaccines. Vaccine 2011Nov8; 29(48):8788-801; http://dx.doi.org/10.1016/j.vaccine.2011.09.077
106. B.G.Weniger, M.J.Papania. Alternative vaccine delivery methods. In:S.A.Plotkin, W.A.Orenstein, P.A.Offi, editors. Vaccines. 6th edition. New York, NY:Elsevier; 2013. pp. 1200-31
107. J.Banchereau, E.Klechevsky, N.Schmitt, R.Morita, K.Palucka, H.Ueno. Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci 2009 Sep; 1174:24-32; http://dx.doi.org/10.1111/j.1749-6632.2009.04999.x
108. M.B.M.Teunissen. Intradermal immunization. Düsseldorf, Germany:Springer-Verlag; 2012